妊娠合并输血依赖型β地中海贫血应用去铁胺（DFO）：一项回顾性研究。
Use of deferoxamine (DFO) in transfusion-dependent β-thalassemia during pregnancy: A retrospective study.
机构信息
Department of Gynecological and Obstetric Sciences and Urological Sciences, University of Rome "Sapienza", Umberto I Hospital, V. le del Policlinico 155, 00161 Rome, Italy.
Department of Gynecological and Obstetric Sciences and Urological Sciences, University of Rome "Sapienza", Umberto I Hospital, V. le del Policlinico 155, 00161 Rome, Italy.
出版信息
Taiwan J Obstet Gynecol. 2020 Jan;59(1):120-122. doi: 10.1016/j.tjog.2019.11.018.
OBJECTIVE
To report cases of use of chelation therapy during pregnancy which resulted in favorable outcomes for the babies.
MATERIALS AND METHODS
In this retrospective cohort study, we described the evolution and outcome of 9 pregnancies in Italian thalassemic women who received deferoxamine (DFO) inadvertently during early pregnancy.
RESULTS
The use of deferoxamine during first trimester did not lead to adverse effects on the fetus or cause major complications for the gestation, although an increase in iron burden was observed after suspending chelation therapy.
CONCLUSION
In our experience, iron-chelation therapy might be administrated in pregnancy where the benefits to the mother outweigh the potential risks to the baby.
目的
报告妊娠期螯合疗法应用的病例，这些病例对婴儿的结局有益。
材料和方法
在这项回顾性队列研究中，我们描述了 9 例意大利地中海贫血妇女在妊娠早期意外接受去铁胺（DFO）治疗的妊娠过程和结局。
结果
在妊娠早期使用去铁胺并未对胎儿产生不良影响，也未导致妊娠出现重大并发症，但在停止螯合治疗后观察到铁负荷增加。
结论
根据我们的经验，在母亲获益大于婴儿潜在风险的情况下，可在妊娠期进行铁螯合治疗。
Zotero 插件